TLS and Kedrion: creating added value for orphan drugs

At Kedrion Biopharma, we have always focused on the research and develop­ment of plasma-derived orphan drugs in­tended for the treatment of rare diseases. Unmet medical needs led us to establish a plant in Siena, Italy, in 2011. Renamed IKOD (Kedrion Orphan Drugs Plant), these facilities are part of a collaboration between Kedrion Biopharma and Toscana Life Sciences Foundation and, in October 2015, they were granted the authorization to produce biological hemoderived experimen­tal therapies for clinical testing by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA).

In the following video, Lorenzo Terranova, IKOD QA Manager and Qualified Person, tells the story of Kedrion Biopharma’s dedication to developing the right treatment for particularly rare diseases.

For more information please contact: [email protected]
error: Content is protected !!